Targeted Therapy with Radium-223 of Bone Metastases

223Ra is a targeted alpha therapy approved for treatment of metastatic prostate cancer with symptomatic bone metastases and without known visceral metastases. It documented an overall survival benefit, increased time to symptomatic skeletal event, improved quality of life and good safety profile in the pivotal trial ALSYMPCA.